FY2026 EPS Estimates for Innate Pharma Reduced by Analyst

Key Points

• HC Wainwright lowered Innate Pharma’s FY2026 EPS estimate to a loss of $0.79 per share from $0.65, while maintaining a “Buy” rating and a $7.00 price target.
• Analyst sentiment remains broadly positive: Innate Pharma has a “Moderate Buy” consensus rating and an average price target of $6.33, with recent upgrades from Leerink Partners and Citigroup.
• Shares opened at $2.15 after a reported 3.2% decline, while institutional investors hold only 0.16% of the company’s stock.

Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA - Free Report) - Equities researchers at HC Wainwright dropped their FY2026 EPS estimates for shares of Innate Pharma in a note issued to investors on Monday, August 10th. HC Wainwright analyst S. Ramakanth now forecasts that the company will earn ($0.79) per share for the year, down from their prior forecast of ($0.65). HC Wainwright currently has a "Buy" rating and a $7.00 target price on the stock. The consensus estimate for Innate Pharma's current full-year earnings is ($0.65) per share. HC Wainwright also issued estimates for Innate Pharma's FY2027 earnings at ($0.59) EPS, FY2028 earnings at ($0.15) EPS, FY2029 earnings at $0.23 EPS and FY2030 earnings at $0.58 EPS.

Other research analysts also recently issued research reports about the stock. UBS Group reiterated a "buy" rating on shares of Innate Pharma in a research note on Tuesday. Weiss Ratings raised shares of Innate Pharma from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Friday, June 26th. Leerink Partners upgraded shares of Innate Pharma from a "market perform" rating to an "outperform" rating and set a $4.00 price objective for the company in a report on Tuesday. Finally, Citigroup raised Innate Pharma from a "buy" rating to an "outperform" rating in a research report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Innate Pharma currently has an average rating of "Moderate Buy" and an average target price of $6.33.

Innate Pharma Trading Down 3.2%

Shares of NASDAQ:IPHA opened at $2.15 on Wednesday. The stock has a fifty day simple moving average of $1.80 and a two-hundred day simple moving average of $1.67. Innate Pharma has a 12-month low of $1.17 and a 12-month high of $2.62.

Institutional Trading of Innate Pharma

Several hedge funds have recently bought and sold shares of the stock. Millennium Management LLC purchased a new stake in shares of Innate Pharma in the fourth quarter worth $36,000. OLD Mission Capital LLC purchased a new position in shares of Innate Pharma during the 4th quarter valued at $50,000. Finally, Jane Street Group LLC purchased a new position in shares of Innate Pharma during the 4th quarter valued at $162,000. Institutional investors own 0.16% of the company's stock.

Innate Pharma Company Profile

Innate Pharma SA is a clinical-stage biotechnology company specializing in the discovery and development of antibody-based therapies that harness the body's innate immune system to combat cancer. Founded in 1999 and headquartered in Marseille, France, the company pioneers novel monoclonal antibodies designed to activate natural killer cells and macrophages, offering a complementary approach to existing immuno-oncology treatments.

The company's lead program, monalizumab, targets the NKG2A immune checkpoint receptor and is being developed in collaboration with AstraZeneca.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source